Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development - Wikidata - wikimedia - TriplyDB

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

http://www.wikidata.org/entity/Q28245741

about

T Cells and Cancer: How Metabolism Shapes Immunity The Warburg effect and drug resistance Cancer Metabolism: A Modeling Perspective Development of Companion Diagnostics Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies Targeted Therapies in Adult B-Cell Malignancies Current Status of Hybrid PET/MRI in Oncologic Imaging PET probes beyond (18)F-FDG Glycotherapy: new advances inspire a reemergence of glycans in medicine Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake GLUT 5 is not over-expressed in breast cancer cells and patient breast cancer tissues In vivo imaging of glucose uptake and metabolism in tumors Novel cancer-targeting SPECT/NIRF dual-modality imaging probe (99m)Tc-PC-1007: synthesis and biological evaluation.Molecular Imaging Probe Development using Microfluidics.Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion.Non-invasive metabolic imaging of brain tumours in the era of precision medicine.The opportunities and challenges of developing imaging biomarkers to study lung function and disease.Validation of novel imaging methodologies for use as cancer clinical trial end-points PET/CT in Oncology: Current Status and Perspectives.Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect.18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis.18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.Putative role of adipose tissue in growth and metabolism of colon cancer cells.From Krebs to clinic: glutamine metabolism to cancer therapy.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Exogenous Fatty Acids Are the Preferred Source of Membrane Lipids in Proliferating Fibroblasts.Molecular imaging of metastatic potential.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand Radiosyntheses using fluorine-18: the art and science of late stage fluorination Implications of Ambient Glucose Variation on the Target-to-Background Ratio of Hepatic Tumors By (18)FDG-PET Imaging.

P2860

Q26766427-20E4CCE5-0BCD-4EAC-83E5-8B8D7B14753B Q26770007-EFB42C5C-4BFC-4281-BF8B-8B2A5C8E7F37 Q26770819-8F946BA2-3C92-4F3D-82CD-20EB37AA6DE8 Q26774670-0E5DF764-9167-4295-8F29-6DE7F111B242 Q26778463-4E50271E-1CA8-4137-A990-1DADBA144F7F Q26783195-C8CF3F5D-B94F-4681-88D5-6D25AF539CD4 Q26825265-9D230EB9-4A63-42BC-95BF-9F15DCFBCF07 Q27004457-C40A3706-0186-4342-836E-74D19F56F45F Q27027997-DD2D0546-62DA-4881-99BE-6561A4CFB231 Q28074096-35F6156E-6698-49E2-9968-E1C4E3142548 Q28384680-77BA1E58-6445-4B31-87CC-74F290CEFFC5 Q28512637-24017728-50A7-454C-865B-5517A286270B Q28743219-712CCD37-E5BA-419A-80B9-4E6DA7E4684D Q28817951-515D8027-DFAF-420B-8382-AD75EC61A3B5 Q30361589-10C1D1BE-F9F1-442C-997F-49916119DF0D Q30463697-70CA360F-26E8-47EF-9413-80454962812F Q30472127-8858BBAD-66FD-4242-B9FB-603C72FFDE45 Q30523931-EE06FDAB-D642-47E7-901A-953D71FEE0A4 Q30907831-B0AC8EDD-45F7-40F3-B92C-2AF8654FC7FA Q30949446-3B81FF8A-7EAA-48D7-96CF-8B52DA414767 Q31115540-747F8CDA-32F6-47E6-8A19-25ACA42F4C11 Q33283655-78C5B566-9FC8-4FDC-B6A3-3940D71A3524 Q33394106-2DD724AB-7388-41D1-8997-A5179363299F Q33665109-6351BA04-EE95-44BA-BD7E-B9A941FBDB8A Q33670824-5B37F042-ABA3-4B2F-8F79-5AA07BACDA35 Q33686825-C04AA546-BD66-4C2B-A50E-958A6BFCB341 Q33724938-DA24D7D7-8393-4BE7-A4C9-7563132525A7 Q33729180-43B81C9C-F57F-449C-B36C-134CF846D820 Q33764812-C29F736E-5073-42BC-9B37-C3F235510E53 Q33766595-E87AB9A4-A8E2-4DCD-A66B-7C73EB8609B9 Q33775762-9B4661F6-A364-4E6D-9C7F-AB27CE3CCE47 Q33808873-448DD15C-586C-4956-BD83-1A601DDDA561 Q33834498-F6224064-BC1E-4B24-8401-4A219151780B Q33887986-FFB04166-0D18-4BEC-B553-6ADC868473DC Q33904647-0DF61DCF-E32E-4DE8-97AA-99B53F2B7A3E Q33917943-508C5E9F-7A7E-4E4C-96AC-D41773C20E14 Q33919290-C3C021B1-77B2-4CE1-9F82-D77087640F92 Q33979930-8C8E4C85-3A4D-48AB-B35A-898980C90D47 Q34074437-C3A962CF-DE00-4098-967F-9E6CE78320F9 Q34080896-7111FE97-15BD-4AA9-950F-3377F769B06F

P2860

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

http://www.wikidata.org/entity/Q28245741

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Progress and promise of FDG-PE ...... and oncologic drug development

@ast

Progress and promise of FDG-PE ...... and oncologic drug development

@en

Progress and promise of FDG-PE ...... and oncologic drug development

@nl

type

label

Progress and promise of FDG-PE ...... and oncologic drug development

@ast

Progress and promise of FDG-PE ...... and oncologic drug development

@en

Progress and promise of FDG-PE ...... and oncologic drug development

@nl

prefLabel

Progress and promise of FDG-PE ...... and oncologic drug development

@ast

Progress and promise of FDG-PE ...... and oncologic drug development

@en

Progress and promise of FDG-PE ...... and oncologic drug development

@nl

P1433

Q28245741-FEC62A43-284D-426D-ACF7-D927726515F7

P1476

Q28245741-6EC695D1-834C-4DEE-B06B-EFFD890D0FED

P2093

Q28245741-2BFDCA3D-55F0-45FC-8E2E-CDE9010CB150

Q28245741-3B71A336-A35F-4A0D-8DD6-2A0C8A230382

Q28245741-5413A632-41A8-4DFB-96BC-3E054EF4EB3F

Q28245741-6B6CB69B-9CCF-414F-9E7F-9BDE1600580A

Q28245741-6BCC4392-0F87-45C4-8753-A44FE93096C5

Q28245741-78B5DA20-A9F3-464F-AA5B-AFD4F6724B59

Q28245741-B0CAF66A-19F8-4CC2-A456-DB6D25052359

Q28245741-C3600367-5654-4D12-B68C-E66928D7534B

Q28245741-CA8E10DA-70E4-41BC-B7D8-D83767B8FAEB

Q28245741-D4FA58F4-C276-4E94-BFED-0702DC1CAB92

P304

Q28245741-5728492E-513A-4F63-8AA6-A8B27248CB4F

P31

Q28245741-BD90B396-60AC-4F50-A230-CDA69E7C5776

P3181

Q28245741-670BDA06-9BC1-4633-9DE7-BD03626621A1

P356

Q28245741-5B9385AE-61DC-4137-B975-E62BCF6F8F50

P407

Q28245741-8CA1CE3C-0B3D-4F6E-8B16-E784D0995829

P433

Q28245741-0CFACA58-9B31-4E7F-8F0C-142DD0BE19C0

P478

Q28245741-92A4A73D-DA51-4D55-984B-51A47E6797CC

P577

Q28245741-EA62847D-B246-4CC4-9542-4B0A1449166C

P698

Q28245741-F08391F6-6A60-4EEA-B378-F161721CECDA

P921

Q28245741-A0BFFFBF-888A-4F04-9A2D-2B7DCB6C1398

P3181

P356

1078-0432.CCR-04-2626

P1433

Clinical Cancer Research

P1476

Progress and promise of FDG-PE ...... and oncologic drug development

@en

P2093

Barry A Siegel

http://www.w3.org/2001/XMLSchema#string

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Bruce Johnson

http://www.w3.org/2001/XMLSchema#string

Caroline C Sigman

http://www.w3.org/2001/XMLSchema#string

Daniel C Sullivan

http://www.w3.org/2001/XMLSchema#string

David A Mankoff

http://www.w3.org/2001/XMLSchema#string

Edward Y Cheng

http://www.w3.org/2001/XMLSchema#string

Gary J Kelloff

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

John M Hoffman

http://www.w3.org/2001/XMLSchema#string

P304

2785-808

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3590002

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-04-2626

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15837727

http://www.w3.org/2001/XMLSchema#string

P921